Rating Change
HC Wainwright & Co. analysts upgraded Crescent Biopharma, Inc. Common Stock (NASDAQ:CBIO) from Neutral to Buy on October 06, 2026.
upgradeNASDAQ:CBIO
Crescent Biopharma, Inc. Common Stock (CBIO) Upgraded to Buy at HC Wainwright & Co.
HC Wainwright & Co. analysts upgraded Crescent Biopharma, Inc.
At publication ·
What changed
Crescent Biopharma, Inc. Common Stock (NASDAQ:CBIO) · upgrade
- Firm
- HC Wainwright & Co.
- Rating
- Neutral to Buy
- Price at event
- $13.57
- Market capitalization
- $213.7M
At a glance
Key takeaways
- HC Wainwright & Co. upgraded Crescent Biopharma (CBIO) from Neutral to Buy on October 6, 2026.
Market Context
Crescent Biopharma, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $13.57 with a market capitalization of $213.7M. The stock has gained 9.0% over the past 52 weeks.
Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. HC Wainwright & Co.'s upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Crescent Biopharma, Inc. Common Stock
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 06, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 14, 2026 | Wedbush | Outperform | N/A |
| Aug 27, 2026 | Wedbush | Outperform | N/A |
| Jun 01, 2026 | HC Wainwright & Co. | Neutral | N/A |
| Mar 02, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View CBIO Stock Page
Frequently Asked Questions
What does the Buy rating mean for CBIO?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Crescent Biopharma, Inc. Common Stock (NASDAQ:CBIO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CBIO forecast page.